Organon (OGN) Non-Current Deferred Tax Liability (2020 - 2026)
Organon (OGN) posted quarterly Non-Current Deferred Tax Liability of $51.0 million for Q2 2026, down 26.09% year-over-year from $69.0 million in Q2 2025, and down 8.93% on a QoQ basis from $56.0 million in Q1 2026.
Organon (OGN) Non-Current Deferred Tax Liability (2020 - 2026) Analysis & Trends
Organon has reported Non-Current Deferred Tax Liability for 7 years, with the latest figure at $51.0 million in Q2 2026.
- Non-Current Deferred Tax Liability for Q2 2026 came in at $51.0 million, down 26.09% year-over-year; the trailing twelve-month figure through Jun 2026 was $51.0 million (down 26.09% YoY), and the FY2025 annual result was $57.0 million, down 65.24% from the prior year.
- Non-Current Deferred Tax Liability eased to $51.0 million in Q2 2026, from $56.0 million in the prior quarter.
- Over five years, Non-Current Deferred Tax Liability peaked at $164.0 million in Q4 2024 and troughed at $2.0 million in Q1 2022.
- A 5-year average of $57.5 million and a median of $53.5 million in 2024 frame the typical range for Non-Current Deferred Tax Liability.
- The widest annual swing landed in 2022, when Non-Current Deferred Tax Liability plunged 98.4%; it then surged 1400.0% in 2023.
- A 5-year view of Non-Current Deferred Tax Liability shows it stood at $127.0 million in 2022, then sank by 62.99% to $47.0 million in 2023, then surged by 248.94% to $164.0 million in 2024, then slumped by 65.24% to $57.0 million in 2025, then slipped by 10.53% to $51.0 million in 2026.
- Per Business Quant data, the three most recent Non-Current Deferred Tax Liability figures were $51.0 million in Q2 2026, $56.0 million in Q1 2026, and $57.0 million in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Organon | 3.61 Bn | 2.48 Bn | 847.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 51.00 Mn |
| Jun 30, 2026 | 51.00 Mn |
| Mar 31, 2026 | 56.00 Mn |
| Mar 31, 2026 | 56.00 Mn |
| Dec 31, 2025 | 57.00 Mn |
| Dec 31, 2025 | 57.00 Mn |
| Sep 30, 2025 | 62.00 Mn |
| Sep 30, 2025 | 62.00 Mn |
| Jun 30, 2025 | 69.00 Mn |
| Jun 30, 2025 | 69.00 Mn |
| Mar 31, 2025 | 69.00 Mn |
| Mar 31, 2025 | 69.00 Mn |
| Dec 31, 2024 | 74.00 Mn |
| Dec 31, 2024 | 74.00 Mn |
| Sep 30, 2024 | 56.00 Mn |
| Sep 30, 2024 | 56.00 Mn |
| Jun 30, 2024 | 60.00 Mn |
| Jun 30, 2024 | 60.00 Mn |
| Mar 31, 2024 | 44.00 Mn |
| Mar 31, 2024 | 44.00 Mn |